For example, high expression of the ADRA2A receptor is associated with better prognosis in patients by inhibiting the PI3K/Akt/mTOR pathway,[18] while the ERBB3 gene regulates epithelial-mesenchymal transition (EMT) through this pathway and affects immune cell infiltration in the tumor microenvironment, thereby influencing patient survival.[19] In addition, mutations in the PIK3CA gene (such as E545K, E542K) and inactivating mutations in PTEN (such as R233) are common in cervical cancer and may affect treatment response.[17] Targeted therapies against this pathway have shown potential. This evidence concerns the gene AKT1 and neoplasm.